Department of Dentistry, Radboud University Medical Center, Nijmegen, The Netherlands.
Department of Oral Medicine, Academic Centre for Dentistry Amsterdam, University of Amsterdam and VU University, Amsterdam, The Netherlands.
Clin Oral Investig. 2023 Dec;27(12):7369-7381. doi: 10.1007/s00784-023-05327-1. Epub 2023 Oct 18.
Haematopoietic cell transplantation (HCT) preceded by a conditioning regimen is an established treatment option for (non)malignant haematologic disorders. We aim to describe the development of hyposalivation over time in HCT recipients, and determine risk indicators.
A multi-centre prospective longitudinal observational study was conducted. Unstimulated (UWS) and stimulated (SWS) whole saliva was collected before HCT, early post-HCT, and after 3, 6, 12, and 18 months. The effect of type of transplantation (allogeneic vs autologous) and intensity (full vs reduced) of the conditioning regimen on hyposalivation (UWS < 0.2 mL/min; SWS < 0.7 mL/min) was explored.
A total of 125 HCT recipients were included. More than half of the patients had hyposalivation early post-HCT; a quarter still had hyposalivation after 12 months. The conditioning intensity was a risk indicator in the development of hyposalivation of both UWS (OR: 3.9, 95% CI: 1.6-10.6) and SWS (OR: 8.2, 95% CI: 2.9-24.6). After 3 and 12 months, this effect was not statistically significant anymore.
Hyposalivation affects the majority of patients early post-HCT. The conditioning intensity and the type of transplantation were significant risk indicators in the development of hyposalivation. The number of prescribed medications, total body irradiation as part of the conditioning regimen and oral mucosal graft-versus-host disease did not influence hyposalivation significantly.
Because of the high prevalence of hyposalivation, HCT recipients will have an increased risk of oral complications. It might be reasonable to plan additional check-ups in the dental practice and consider additional preventive strategies.
造血细胞移植(HCT)在前瞻性预处理方案后是(非)恶性血液病的一种既定治疗选择。我们旨在描述 HCT 受者唾液分泌减少的发展过程,并确定其风险指标。
进行了一项多中心前瞻性纵向观察研究。在 HCT 前、HCT 后早期以及 3、6、12 和 18 个月后收集非刺激性(UWS)和刺激性(SWS)全唾液。探索了移植类型(异体与自体)和预处理方案强度(完全与减量化)对唾液分泌减少(UWS<0.2 mL/min;SWS<0.7 mL/min)的影响。
共纳入 125 例 HCT 受者。超过一半的患者在 HCT 后早期出现唾液分泌减少;四分之一的患者在 12 个月后仍存在唾液分泌减少。预处理强度是 UWS(OR:3.9,95%CI:1.6-10.6)和 SWS(OR:8.2,95%CI:2.9-24.6)发展为唾液分泌减少的风险指标。但在 3 个月和 12 个月后,这种影响不再具有统计学意义。
唾液分泌减少在 HCT 后早期影响大多数患者。预处理强度和移植类型是唾液分泌减少发展的显著风险指标。处方药物数量、预处理方案中的全身放疗以及口腔黏膜移植物抗宿主病对唾液分泌减少的影响并不显著。
由于唾液分泌减少的高患病率,HCT 受者将有更高的口腔并发症风险。在牙科实践中计划额外的检查并考虑额外的预防策略可能是合理的。